Inactive Instrument

Insiders Axovant Sciences Ltd Nasdaq

Equities

Sio Gene Therapies Ends Gene Therapy Program for Parkinson's Disease, Names New CEO	22-02-01	MT
Sio Gene Therapies Inc. Announces Executive Changes	22-01-31	CI
Sio Gene Therapies Inc. Appoints David Nassif, J.D. to Its Board of Directors	22-01-31	CI
Sio Gene Therapies : Chief Research and Development Officer Gavin Corcoran to Leave Next Month; Unveils Chief Medical Officer Role	21-10-21	MT
Sio Gene Therapies Inc. Announces Executive Changes	21-10-21	CI
Axovant Sciences Announces Formation of Arvelle Therapeutics; Mark Altmeyer to Step Down as Chief Commercial Officer	19-02-14	CI
Axovant Sciences Ltd. Announces Management Changes	18-02-12	CI
Axovant Sciences Announces Changes to Board of Directors	17-06-06	CI
Axovant Sciences Ltd. Announces Management Changes	17-06-06	CI
Axovant Sciences Announces Management Changes	17-04-10	CI
Axovant Sciences Ltd Appoints Tony Vernon to its Board of Directors	17-04-10	CI
Axovant Sciences Ltd Appoints Kate Falberg to its Board of Directors	17-04-10	CI
Axovant Sciences Ltd Appoints Marion Mccourt as President, Chief Operating Officer	17-04-10	CI
Axovant Sciences Ltd. Appoints Gary P. Pisano to Board of Directors	16-05-13	CI

No results for this search